REGENXBIO Q1 net loss $63.3M; RGX-202 selects pivotal dose; cash $380.5M

REGENXBIO Inc.

2024-Q1 EPS reported -$1.38 revenue$15,622,000

Net loss $63.3M ($1.38 diluted EPS) vs $66.7M ($1.53) YoY; revenue $15.6M, down from $19.1M.
Cash, equivalents and marketable securities $380.5M (up from $314.1M), runway into 2026.
RGX-202 Duchenne: pivotal dose DL2 selected; second patient showed 20.9% microdystrophin expression, 90% CK reduction.
ABBV-RGX-314 DR: positive interim ALTITUDE data; end-of-Phase II meeting FDA Q1 2025; pivotal trial H1 2025.
RGX-121 BLA filing on track for 2024 via accelerated approval; potential Priority Review Voucher.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REGENXBIO Inc. reported the first quarter ending March 31, 2024 results: revenue $15.6 million.

Period: the first quarter ending March 31, 2024
Revenue: $15.6 million
Result: reported results

Exact text from the filing

and pre-funded warrants completed in March 2024, and was partially offset by cash used to fund operating activities during the first quarter of 2024. Revenues: Revenues were $15.6 million for the three months ended March 31, 2024, compared to $19.1 million for the three months ended March 31, 2023. The decrease was primarily attributable to non-recurring

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

REGENXBIO Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-055656

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.